Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain (RAQUEL)

• ClinicalTrials.gov Identifier: NCT03692403
• Recruitment Status: Completed
• First Posted: October 2, 2018
• Last Update Posted: October 4, 2022
• Sponsor: Ferring Pharmaceuticals
• Information provided by (Responsible Party): Ferring Pharmaceuticals

Tracking Information

• First Submitted Date: September 14, 2018
• First Posted Date: October 2, 2018
• Last Update Posted Date: October 4, 2022
• Actual Study Start Date: November 28, 2018
• Actual Primary Completion Date: February 14, 2022 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: September 28, 2018)

Changes in the mean daily Numerical Rating Scale (NRS) scores compared to baseline for the worst endometriosis related pain. [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]

Assessed daily by participants in an e-Diary. NRS is a 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: December 11, 2020)

• Changes in the mean daily Numerical Rating Scale (NRS) scores for the worst endometriosis-related pain on days with menstrual bleeding and for the worst endometriosis-related pain on days with no menstrual bleeding [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]
  Assessed daily by participants in an e-Diary. NRS is a 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.
• Changes in the mean daily Numerical Rating Scale (NRS) scores for the worst endometriosis-related pain. [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]
  Assessed daily by participants in an e-Diary. NRS is a 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.
• Changes in the mean daily Numerical Rating Scale (NRS) scores for the worst dysmenorrhea. [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]
  Assessed daily by participants in an e-Diary. NRS is a 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.
• Changes in the mean daily Numerical Rating Scale (NRS) scores for the worst non-menstrual pelvic pain. [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]
  Assessed daily by participants in an e-Diary. NRS is a 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.
• Changes in the mean daily Numerical Rating Scale (NRS) scores for the worst dyspareunia on days with sexual intercourse. [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]
  Assessed daily by participants in an e-Diary. NRS is a 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.
• Frequency of avoiding sexual intercourse due to expected pain [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]
  Assessed daily by participants in an e-Diary
• Changes in the mean daily scores for the worst impact of endometriosis-related pain on the subject's ability to function. [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]
  Assessed daily by participants in an e-Diary.
• Changes in the mean weekly scores of the Endometriosis Health Profile-30 (EHP-30) pain impact domain. [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]
  Assessed weekly by participants in an e-Diary. EHP-30 is a quality-of-life questionnaire. Score ranges from 0-100 and lower score denotes improvement.
• Changes in vaginal bleeding pattern. [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]
  Assessed participants by subjects in an e-Diary
• Percentage of days with mild and/or strong rescue analgesics used [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]
  Assessed daily by participants in an e-Diary
• Total and average doses of mild and/or strong rescue analgesics used [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]
  Assessed daily by participants in an e-Diary
• Responder rate [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]
  Assessed as ≥30%, ≥50% and ≥70% reduction from the baseline in mean daily NRS score for the worst endometriosis-related pain, dysmenorrhea and non-menstrual pelvic pain and for the worst endometriosis-related pain impact
• Changes in the mean individual and total symptom and sign severity scores [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]
  Assessed by the Biberoglu and Behrman (B&B) scale which is a 4-point scale with 0=none and 3=severe.
• Changes in the Endometriosis Health Profile-30 (EHP-30) scores [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]
  Assessed by the EHP-30 quality-of-life questionnaire completed by subjects. Score ranges from 0-100 with lower score denoting improvement.
• Changes in Patient Global Impression of Severity (PGIS) scores [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]
  Assessed by the PGIS scale completed by participants. PGIS is a 6-point scale depicting a subject's rating of their current conditions from "good" to "bad".
• Patient Global Impression of Change (PGIC) scores [ Time Frame: At cycle 4 (around 4 months, each cycle is approximately 28 days) ]
  Assessed by the PGIC scale completed by participants. PGIC is a 7-point scale depicting a patient's rating of their overall improvement from "good" to "bad".
• Plasma concentration of quinagolide and metabolites [ Time Frame: Within 5 days after first ring insertion and at around 1 month, 3 months, 3.5 months and 4 months after baseline (each cycle is approximately 28 days) ]
  Assessed by blood samples collection
• Serum levels of mid-luteal phase progesterone [ Time Frame: At baseline and cycle 4 (around 3.5 months, each cycle is approximately 28 days) ]
  Assessed by blood samples collection
• Proportion of subjects with serum mid-luteal progesterone levels ≥25 nmol/L (7.9 ng/ml) [ Time Frame: At baseline and cycle 4 (around 3.5 months, each cycle is approximately 28 days) ]
  Assessed by blood samples collection
• Serum levels of mid-luteal estradiol, prolactin, thyroid-stimulating hormone (TSH) and insulin-like growth factor-1 (IGF-1) [ Time Frame: At baseline and cycle 4 (around 3.5 months, each cycle is approximately 28 days) ]
  Assessed by blood samples collection
• Changes in bone turnover markers, determined by bone resorption marker serum C-terminal crosslinking telopeptide of type 1 collagen (s-CTx) and bone formation marker serum procollagen type I N propeptide (s-PINP) [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]
  Assessed by blood samples collection
• Number of subjects with no changes, non-significant changes and significant changes in ECG [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]
  Assessed by 12-lead ECG
• Proportion of subjects with abnormal clinically significant echocardiography findings indicating valvular heart disease [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]
  Assessed by echocardiography
• Proportion of subjects identified with potential impulse control disorders [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]
  Assessed by the questionnaire for impulsive-compulsive disorders completed by subjects
• Frequency and intensity of adverse events [ Time Frame: From signing informed consent through study completion, around 7 months ]
  Assessed by an Adverse Events Log completed by the Investigator
• Changes in circulating levels of clinical chemistry parameters [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months) and cycle 5 (around 5 months, each cycle is approximately 28 days) ]
  Assessed by blood samples collection
• Changes in circulating levels of clinical haematology parameters [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months) and cycle 5 (around 5 months, each cycle is approximately 28 days) ]
  Assessed by blood samples collection
• Changes in urinalysis parameters (protein, glucose, bilirubin, pH, nitrite, ketone, urobilinogen, blood, leukocytes, and specific gravity) [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]
  Assessed by urine sample collection (dip-stick test)
• Proportion of participants with markedly abnormal changes in circulating levels of clinical chemistry parameters [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months) and cycle 5 (around 5 months, each cycle is approximately 28 days) ]
  Assessed by blood samples collection
• Proportion of participants with markedly abnormal changes in circulating levels of clinical haematology parameters [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months) and cycle 5 (around 5 months, each cycle is approximately 28 days) ]
  Assessed by blood samples collection
• Proportion of participants with markedly abnormal changes in urinalysis parameters [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]
  Assessed by urine samples collection
• Frequency and intensity of ring acceptability parameters [ Time Frame: From baseline to menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]
  Assessed by a questionnaire completed by participants, addressing ring insertion/removal, any feeling of the ring while the ring is in the body, any feeling of the ring during sexual intercourse if applicable and any experience of ring falling out or breaking.

Original Secondary Outcome Measures (submitted: September 28, 2018)

• Changes in the mean daily Numerical Rating Scale (NRS) scores for the worst endometriosis-related pain on days with menstrual bleeding and for the worst endometriosis-related pain on days with no menstrual bleeding [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months, each cycle is approximately 28 days) ]
  Assessed daily by participants in an e-Diary. NRS is a 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.
• Changes in the mean daily Numerical Rating Scale (NRS) scores for the worst endometriosis-related pain. [ Time Frame: From baseline to menstrual cycle 8 (around 8 months, each cycle is approximately 28 days) ]
  Assessed daily by participants in an e-Diary. NRS is a 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.
• Changes in the mean daily Numerical Rating Scale (NRS) scores for the worst dysmenorrhea. [ Time Frame: From baseline to menstrual cycle 8 (around 8 months, each cycle is approximately 28 days) ]
  Assessed daily by participants in an e-Diary. NRS is a 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.
• Changes in the mean daily Numerical Rating Scale (NRS) scores for the worst non-menstrual pelvic pain. [ Time Frame: From baseline to menstrual cycle 8 (around 8 months, each cycle is approximately 28 days) ]
  Assessed daily by participants in an e-Diary. NRS is a 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.
• Changes in the mean daily Numerical Rating Scale (NRS) scores for the worst dyspareunia on days with sexual intercourse. [ Time Frame: From baseline to menstrual cycle 8 (around 8 months, each cycle is approximately 28 days) ]
  Assessed daily by participants in an e-Diary. NRS is a 11-point scale, with 0 indicating no pain and 10 indicating the worst imaginable pain.
• Frequency of avoiding sexual intercourse due to expected pain [ Time Frame: From baseline to menstrual cycle 8 (around 8 months, each cycle is approximately 28 days) ]
  Assessed daily by participants in an e-Diary
• Changes in the mean daily scores for the worst impact of endometriosis-related pain on the subject's ability to function. [ Time Frame: From baseline to menstrual cycle 8 (around 8 months, each cycle is approximately 28 days) ]
  Assessed daily by participants in an e-Diary.
• Changes in the mean weekly scores of the Endometriosis Health Profile-30 (EHP-30) pain impact domain. [ Time Frame: From baseline to menstrual cycle 8 (around 8 months, each cycle is approximately 28 days) ]
  Assessed weekly by participants in an e-Diary. EHP-30 is a quality-of-life questionnaire. Score ranges from 0-100 and lower score denotes improvement.
• Changes in vaginal bleeding pattern. [ Time Frame: From baseline to menstrual cycle 8 (around 8 months, each cycle is approximately 28 days) ]
  Assessed participants by subjects in an e-Diary
• Percentage of days with mild and/or strong rescue analgesics used [ Time Frame: From baseline to menstrual cycle 8 (around 8 months, each cycle is approximately 28 days) ]
  Assessed daily by participants in an e-Diary
• Total and average doses of mild and/or strong rescue analgesics used [ Time Frame: From baseline to menstrual cycle 8 (around 8 months, each cycle is approximately 28 days) ]
  Assessed daily by participants in an e-Diary
• Responder rate [ Time Frame: From baseline to menstrual cycle 8 (around 8 months, each cycle is approximately 28 days) ]
  Assessed as ≥30%, ≥50% and ≥70% reduction from the baseline in mean daily NRS score for the worst endometriosis-related pain, dysmenorrhea and non-menstrual pelvic pain and for the worst endometriosis-related pain impact
• Changes in the mean individual and total symptom and sign severity scores [ Time Frame: From baseline to menstrual cycle 4 (around 4 months) and cycle 8 (around 8 months, each cycle is approximately 28 days) ]
  Assessed by the Biberoglu and Behrman (B&B) scale which is a 4-point scale with 0=none and 3=severe.
• Changes in the Endometriosis Health Profile-30 (EHP-30) scores [ Time Frame: From baseline to menstrual cycle 8 (around 8 months, each cycle is approximately 28 days) ]
  Assessed by the EHP-30 quality-of-life questionnaire completed by subjects. Score ranges from 0-100 with lower score denoting improvement.
• Changes in Patient Global Impression of Severity (PGIS) scores [ Time Frame: From baseline to menstrual cycle 4 (around 4 months) and cycle 8 (around 8 months, each cycle is approximately 28 days) ]
  Assessed by the PGIS scale completed by participants. PGIS is a 6-point scale depicting a subject's rating of their current conditions from "good" to "bad".
• Patient Global Impression of Change (PGIC) scores [ Time Frame: From baseline to menstrual cycle 4 (around 4 months) and cycle 8 (around 8 months, each cycle is approximately 28 days) ]
  Assessed by the PGIC scale completed by participants. PGIC is a 7-point scale depicting a patient's rating of their overall improvement from "good" to "bad".
• Plasma concentration of quinagolide and metabolites [ Time Frame: Within 5 days after first ring insertion, and at around 2 weeks, 1 month, 3 months, 3.5 months, 4 months, 7 months, 7.5 months, and 8 months after baseline (each cycle is approximately 28 days) ]
  Assessed by blood samples collection
• Serum levels of mid-luteal phase progesterone [ Time Frame: At baseline and at the middle of menstrual cycle 1 (around 2 weeks), cycle 4 (around 3.5 months), and cycle 8 (7.5 months, each cycle is approximately 28 days) ]
  Assessed by blood samples collection
• Proportion of subjects with serum mid-luteal progesterone levels ≥25 nmol/L (7.9 ng/ml) [ Time Frame: At baseline and at the middle of menstrual cycle 1 (around 2 weeks), cycle 4 (around 3.5 months), and cycle 8 (7.5 months, each cycle is approximately 28 days) ]
  Assessed by blood samples collection
• Serum levels of mid-luteal estradiol, prolactin, thyroid-stimulating hormone (TSH) and insulin-like growth factor-1 (IGF-1) [ Time Frame: At baseline and at the middle of menstrual cycle 1 (around 2 weeks), cycle 4 (around 3.5 months), and cycle 8 (7.5 months, each cycle is approximately 28 days) ]
  Assessed by blood samples collection
• Changes in bone turnover markers, determined by bone resorption marker serum C-terminal crosslinking telopeptide of type 1 collagen (s-CTx) and bone formation marker serum procollagen type I N propeptide (s-PINP) [ Time Frame: From baseline to menstrual cycle 4 (around 4 months) and cycle 8 (around 8 months, each cycle is approximately 28 days) ]
  Assessed by blood samples collection
• Number of subjects with no changes, non-significant changes and significant changes in ECG [ Time Frame: From baseline to menstrual cycle 4 (around 4 months) and cycle 8 (around 8 months, each cycle is approximately 28 days) ]
  Assessed by 12-lead ECG
• Proportion of subjects with abnormal clinically significant echocardiography findings indicating valvular heart disease [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months) and cycle 8 (around 8 months, each cycle is approximately 28 days) ]
  Assessed by echocardiography
• Proportion of subjects identified with potential impulse control disorders [ Time Frame: At menstrual cycle 4 (around 4 months) and cycle 8 (around 8 months, each cycle is approximately 28 days) ]
  Assessed by the questionnaire for impulsive-compulsive disorders completed by subjects
• Frequency and intensity of adverse events [ Time Frame: From signing informed consent through study completion, around 12 months ]
  Assessed by an Adverse Events Log completed by the Investigator
• Changes in circulating levels of clinical chemistry parameters [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months), cycle 8 (around 8 months), and cycle 10 (around 10 months, each cycle is approximately 28 days) ]
  Assessed by blood samples collection
• Changes in circulating levels of clinical haematology parameters [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months), cycle 8 (around 8 months), and cycle 10 (around 10 months, each cycle is approximately 28 days) ]
  Assessed by blood samples collection
• Changes in urinalysis parameters (protein, glucose, bilirubin, pH, nitrite, ketone, urobilinogen, blood, leukocytes, and specific gravity) [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months) and cycle 8 (around 8 months, each cycle is approximately 28 days) ]
  Assessed by urine sample collection (dip-stick test)
• Proportion of participants with markedly abnormal changes in circulating levels of clinical chemistry parameters [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months), cycle 8 (around 8 months), and cycle 10 (around 10 months, each cycle is approximately 28 days) ]
  Assessed by blood samples collection
• Proportion of participants with markedly abnormal changes in circulating levels of clinical haematology parameters [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months), cycle 8 (around 8 months), and cycle 10 (around 10 months, each cycle is approximately 28 days) ]
  Assessed by blood samples collection
• Proportion of participants with markedly abnormal changes in urinalysis parameters [ Time Frame: At baseline and at menstrual cycle 4 (around 4 months), cycle 8 (around 8 months), and cycle 10 (around 10 months, each cycle is approximately 28 days) ]
  Assessed by urine samples collection
• Frequency and intensity of ring acceptability parameters [ Time Frame: From baseline to menstrual cycle 8 (around 8 months, each cycle is approximately 28 days) ]
  Assessed by a questionnaire completed by participants, addressing ring insertion/removal, any feeling of the ring while the ring is in the body, any feeling of the ring during sexual intercourse if applicable and any experience of ring falling out or breaking.

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain
• Official Title: A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial Assessing Efficacy, Safety, Dose-response of Quinagolide Vaginal Rings Administered Sequentially for 4 Menstrual Cycles in Women With Moderate-Severe Endometriosis-related Pain
• Brief Summary: To evaluate the efficacy of three doses of quinagolide administered as an extended-release vaginal ring compared to placebo on reduction of moderate to severe endometriosis-related pain
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Double (Participant, Investigator); Primary Purpose: Treatment
• Condition: Endometriosis-related Pain

Intervention

• Drug: Quinagolide 360 µg
  Vaginal ring containing quinagolide 360 µg for daily releases
  Other Name: FE 999051
• Drug: Quinagolide 720 µg
  Vaginal ring containing quinagolide 720 µg for daily releases
  Other Name: FE 999051
• Drug: Quinagolide 1080 µg
  Vaginal ring containing quinagolide 1080 µg for daily releases
  Other Name: FE 999051
• Drug: Placebo
  Matching placebo

Study Arms

• Experimental: Quinagolide 360 µg
  Vaginal ring containing Quinagolide 360 μg, with daily target release rate of 4.5 μg
  Intervention: Drug: Quinagolide 360 µg
• Experimental: Quinagolide 720 µg
  Vaginal ring containing Quinagolide 720 μg, with daily target release rate of 9 μg
  Intervention: Drug: Quinagolide 720 µg
• Experimental: Quinagolide 1080 µg
  Vaginal ring containing Quinagolide 1080 μg, with daily target release rate of 13.5 μg
  Intervention: Drug: Quinagolide 1080 µg
• Placebo Comparator: Placebo
  Vaginal ring containing matching placebo
  Intervention: Drug: Placebo

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: November 17, 2021): 22
• Original Estimated Enrollment (submitted: September 28, 2018): 280
• Actual Study Completion Date: February 14, 2022
• Actual Primary Completion Date: February 14, 2022 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Pre-menopausal females aged ≥18 years at time of signing informed consent(s).
• Body mass index (BMI) of 18-42 kg/m2 (both inclusive) at screening.
• Initial confirmation of endometriosis by laparoscopy or laparotomy within the last 10 years before the run-in visit or visualization of persistent endometrioma by repeat ultrasound.
• Transvaginal ultrasound documenting a uterus with no clinically significant abnormalities and presence of at least one ovary with no clinically significant abnormalities (with the exception of endometrioma) at the run-in visit.
• Having moderate to severe endometriosis-related pain.
• Willing to use a non-hormonal barrier method (i.e. condom) for contraception from randomization to the end-of-trial. This is not required if adequate contraception is achieved by vasectomy of the sexual partner or surgical sterilisation of the subject.
• Willing to avoid the use of vaginal douches or any other intravaginally administered medications or devices from randomization to the end of treatment.
• Willing to change usual analgesics to rescue analgesics as permitted by protocol for endometriosis-related pain from the start of run-in to the end-of-trial.

Exclusion Criteria:

• Use of depot medroxyprogesterone acetate (MPA) within 10 months of the start of run-in.
• Use of gonadotropin releasing hormone (GnRH) agonists (3 months depot) or dopamine agonists within 6 months of the start of run-in.
• Use of GnRH agonists (1 month depot) or intrauterine device within 3 months of the start of run-in.
• Use of GnRH antagonist, combined oral contraceptive pill or progestin-only pill within 1 month of the start of run-in.
• Undiagnosed abnormal vaginal bleeding.
• History of no relief of endometriosis related pain after any medical therapy or surgery. However, history of partial pain relief, discontinuation due to side effects are not exclusionary.
• Known bone diseases (e.g. osteoporosis, Paget's disease and osteomalacia) affecting bone resorption or bone formation markers.
• Any significant abnormal findings of heart examinations before randomization.

Sex/Gender

• Sexes Eligible for Study: Female
• Gender Based Eligibility: Yes

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT03692403
• Other Study ID Numbers: 000165
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: Ferring Pharmaceuticals
• Original Responsible Party: Same as current
• Current Study Sponsor: Ferring Pharmaceuticals
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Director: Global Clinical Compliance; Ferring Pharmaceuticals

• PRS Account: Ferring Pharmaceuticals
• Verification Date: October 2022